Provided by Tiger Trade Technology Pte. Ltd.

XTL Biopharmaceuticals

2.71
0.0000
Volume:805
Turnover:2K
Market Cap:6.66M
PE:-0.87
High:2.71
Open:2.71
Low:2.71
Close:2.78
52wk High:10.28
52wk Low:2.01
Shares:2.46M
Float Shares:1.38M
Volume Ratio:0.62
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1316
EPS(LYR):-5.9716
ROE:-29.30%
ROA:-21.01%
PB:-26.22
PE(LYR):-0.45

Loading ...

Company Profile

Company Name:
XTL Biopharmaceuticals
Exchange:
NASDAQ
Establishment Date:
1993
Employees:
5
Office Location:
85 Medinat Hayehudim St.,Herzliya,Israel
Zip Code:
4676670
Fax:
- -
Introduction:
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Directors

Name
Position
Noam Band
Chief Executive Officer and Director
Shlomo Shalev
Non-Executive Director and Chairman of the Board
Alexander Rabinovich
Non-Executive Director
Iris Shapira Yalon
Non-Executive and External Director
Osnat Hillel Fain
Non-Executive and External Director

Shareholders

Name
Position
Noam Band
Chief Executive Officer and Director
Niv Segal
Chief Financial Officer